From essential medicine to illicit commodity: new EU report reveals how ketamine diversion is fuelling the illicit market in Europe

Ketamine produced legitimately outside the EU to make medicines is increasingly finding its way onto Europe’s illicit drug market, according to a new report published today by the EU Drugs Agency (EUDA). The study, Ketamine in Europe, provides the first comprehensive multi-country intelligence picture of how organised criminal networks are exploiting legitimate pharmaceutical supply chains in Europe and the implications this may have for public health and law enforcement. The report was produced within the framework of the European Multidisciplinary Platform Against Criminal Threats (EMPACT…